Answers are grounded in this paper and cite their sources.
Chimeric antigen receptor T‐cell (CAR‐T) therapy has achieved remarkable success in hematologic malignancies but continues to face multiple biological and engineering barriers in solid tumors. Tumor antigen heterogeneity, antigen loss, immunosuppressive tumor microenvironments (TMEs), and T‐cell dysfunction collectively limit durable responses. A central challenge is that most current CAR‐T platforms remain structurally fixed and cannot adapt to evolving resistance mechanisms. These limitations have prompted growing interest in programmable immunotherapy strategies capable of responding to tumor evolution. In this review, we discuss the emerging potential of mRNA‐engineered nanobody platforms based on the variable domains of camelid heavy‐chain‐only antibodies (VHHs) as next‐generation tools for overcoming CAR‐T resistance in solid tumors. We summarize advances in nanobody engineering, mRNA delivery, lipid nanoparticle (LNP) systems, and programmable CAR designs that may improve tumor targeting, reduce immune exhaustion, and enhance therapeutic adaptability. We further explore how the convergence of mRNA engineering and nanobody technologies enable adaptive immune programming through modular and reconfigurable therapeutic designs. Finally, we discuss future directions, including AI‐assisted nanobody discovery, advanced mRNA engineering platforms, real‐time tumor monitoring, and resistance‐adaptive immunotherapies. Together, these advances position programmable immunotherapy as a promising framework for overcoming resistance and improving therapeutic adaptability in solid tumors.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: